
Pioneering Leap for Friedreich’s Ataxia Treatment: Larimar Therapeutics Announces Encouraging Phase 2 Results for Nomlabofusp
BALA CYNWYD, PA — The clinical-stage biotech firm Larimar Therapeutics has reported promising top-line data from its Phase 2 dose exploration study. The groundbreaking study tested the medication ‘nomlabofusp’ on …
Pioneering Leap for Friedreich’s Ataxia Treatment: Larimar Therapeutics Announces Encouraging Phase 2 Results for Nomlabofusp Read More